|
|
NEW ON THE MARKET
|
|
New therapeutic strategy in type 2 diabetes mellitus: incretin mimetic exenatide (BYETTA)
Bupropion (ELONTRIL) for depression
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Jikei Heart-study with valsartan: advantage only because of open design?
Coronary angioplasty without effect on prognosis of stable angina
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Herpes zoster: brivudine (ZOSTEX) better than aciclovir (ZOVIRAX)?
Smoking and COLD: the definition of "pack-years"
|
|
|
IN BRIEF
|
|
No approval of the cox-2-inhibitor etoricoxib (ARCOXIA) in the US
Adjuvanted influenza vaccine FLUAD: no proven relevant clinical advantage
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Does clopidogrel (PLAVIX, ISCOVER) worsen psoriasis?
|
|
|
SIDE EFFECTS
|
|
Valvular heart disease: measures taken against ergoline dopamine agonists
About the risk for hip fracture due to proton pump inhibitors
Postmenopausal osteoporosis: atrial fibrillation due to bisphosphonates?
Desmopressin (e.g. MINIRIN) - nasal spray not for enuresis nocturna
|
|